ORYZON appoints Michael T. Ropacki, PhD as Vice President of Clinical Development for its CNS epigenetic program
MADRID, SPAIN and CAMBRIDGE MA.
• Dr. Ropacki is a US pharmaceutical industry thought leader in Alzheimer’s disease and CNS disorders
• The first Oryzon senior leadership member permanently based in the US
Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced yesterday January 6th the appointment of Dr. Michael T. Ropacki as Vice President of Clinical and Product Development during the presentation made within the 2nd Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology at the Marines' Memorial Club in San Francisco (USA). Dr. Ropacki is the first Oryzon senior leadership team member to be based permanently in the US since the company was listed on the Spanish Market and is a key element for Oryzon’s new stage of growth and a milestone for company.